dan

Laidlaw Capital Markets is pleased to have been Co-Lead Bookrunner on Cingulate Inc's (CING) $25,000,000 Offering. Cingulate utilizes its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation products. Read Article: https://finance-yahoo-com.cdn.ampproject.org/c/s/finance.yahoo.com/amphtml/news/cingulate-inc-announces-pricing-25-020500801.html  

Laidlaw Capital Markets is pleased to be Financial Advisor on the MEI Pharma Inc’s $52,325,000 Follow-On Offering alongside Jefferies, Stifel, and Wells Fargo.” Link: https://www.meipharma.com/press-releases/mei-pharma-announces-closing-public-offering-common-stock-0

Laidlaw Capital Markets is pleased to be Financial Advisor on the EyePoint Pharmaceutical Inc’s $115,400,000 Follow-On Offering alongside Cowen and Guggenheim Securities

Laidlaw Capital Markets is pleased to have Co-Managed the $655,000,000 Guggenheim Active Allocation Trust offering alongside Bank of America, Morgan Stanley, & Wells Fargo.

Laidlaw Capital Markets is pleased to have Co-Managed the $2,040,000 Blackrock ESG Capital Allocation Trust offering alongside Bank of America, Morgan Stanley, UBS, & Wells Fargo    

Independent advisor platforms are attracting a growing number of international advisors to their networks. What is driving this growth and what are the benefits for advisors who opt for this independent model? The entrepreneurial spirit is strong in the advisory industry, with a growing number of international advisors now making the jump to independence. But launching Read More...

Laidlaw Wealth Management has hired an advisor from Wells Fargo’s international unit in Miami as the firm looks to expand its coverage of Latin America with the opening of a new office. John Cross joined the firm on May 5 after having spent nearly seven years at the wirehouse’s offices in Coral Gables, according to Read More...

Laidlaw Capital Markets is pleased to have served as a Financial Advisor to Delcath Systems on their $20,000,000 Follow-on Offering alongside Canaccord Genuity and Roth Capital

Laidlaw Capital Markets is pleased to have served as a Lead Manager on a $147,500,000 Follow-On Offering for Curis Inc (CRIS). See press release